Nymox Pharma (NYMX) Reports Statistical Significance Achieved on NX-1207 Phase 2 Follow Ups
Tweet
Share
E-mail
Nymox Pharmaceutical Corporation (Nasdaq: NYMX) reports podium presentation of new data on the long term safety and efficacy of the Company's NX-1207 for benign prostatic hyperplasia (BPH) at the Annual Meeting of the North Central Section of the American Urological Association in Rancho Mirage, CA on October 19, 2011.
Neal Shore MD FACS, the Medical Director of the Carolina Urologic Research Center and a highly experienced clinical trial investigator, reviewed the progress of the clinical trial program for NX-1207 to date and presented new analyses of long-term follow-up data for up to 6 ½ years after a single treatment with NX-1207.
According to the peer-reviewed abstract at the meeting, "Overall at 3 to 6 ½ years after a single treatment of NX-1207, 37 to 55% of subjects required no surgical treatments or medication for their BPH. All Phase 2 follow-up study efficacy results reached statistical significance and there were no sexual side effects or significant adverse safety events attributable to study drug." The authors of the abstract were Dr. Shore, Barrett Cowan MD FACS of Denver, CO, Barton Wachs MD FACS of Long Beach, CA, Chris Threatt MD of Atherton, CA, Rafael Wurzel MD CPI of New Britain, CT, Kevin Cline MD of Shreveport, LA, and Sheldon Freedman MD FACS of Las Vegas, NV.
Dr. Shore said, "Ongoing follow-up from prior trials of NX-1207 continues to demonstrate a favorable durability of effect".
Neal Shore MD FACS, the Medical Director of the Carolina Urologic Research Center and a highly experienced clinical trial investigator, reviewed the progress of the clinical trial program for NX-1207 to date and presented new analyses of long-term follow-up data for up to 6 ½ years after a single treatment with NX-1207.
According to the peer-reviewed abstract at the meeting, "Overall at 3 to 6 ½ years after a single treatment of NX-1207, 37 to 55% of subjects required no surgical treatments or medication for their BPH. All Phase 2 follow-up study efficacy results reached statistical significance and there were no sexual side effects or significant adverse safety events attributable to study drug." The authors of the abstract were Dr. Shore, Barrett Cowan MD FACS of Denver, CO, Barton Wachs MD FACS of Long Beach, CA, Chris Threatt MD of Atherton, CA, Rafael Wurzel MD CPI of New Britain, CT, Kevin Cline MD of Shreveport, LA, and Sheldon Freedman MD FACS of Las Vegas, NV.
Dr. Shore said, "Ongoing follow-up from prior trials of NX-1207 continues to demonstrate a favorable durability of effect".
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Home Depot expands executive roles, grants $500K in restricted stock
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
